Sanofi India (BOM:500674) Cyclically Adjusted Book per Share: ₹0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
77 GF Score
Price ₹3,369.25
GF Value ₹4,404.20
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Cyclically Adjusted Book per Share?

Sanofi India BOM:500674 -0.54% 77 Cyclically Adjusted Book per Share is ₹0.00 as of Mar. 2026. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,404.20 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Sanofi India's adjusted book value per share for the three months ended in Mar. 2026 was ₹0.000. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sanofi India's average Cyclically Adjusted Book Growth Rate was -5.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Sanofi India was 5.20% per year. The lowest was -3.20% per year. And the median was 0.75% per year.

As of today (2026-07-28), Sanofi India's current stock price is ₹3369.25. Sanofi India's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₹0.00. Sanofi India's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sanofi India was 7.38. The lowest was 2.90. And the median was 4.51.


Sanofi India  (BOM:500674) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sanofi India was 7.38. The lowest was 2.90. And the median was 4.51.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Sanofi India Cyclically Adjusted Book per Share Related Terms


Sanofi India Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Sanofi India's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi India Cyclically Adjusted Book per Share Chart

Sanofi India Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 998.83 1,021.17 1,012.69 977.28 925.42

Sanofi India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 948.79 0.00 925.42 0.00

BOM:500674 vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Sanofi India's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi India Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi India's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sanofi India's Cyclically Adjusted PB Ratio falls into.


BOM:500674
77GF Score
Sanofi India Ltd BOM:500674
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi India Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sanofi India's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/164.2724*164.2724
=0.000

Current CPI (Mar. 2026) = 164.2724.

Sanofi India Quarterly Data

Book Value per Share CPI Adj_Book
201606 756.806 105.961 1,173.283
201609 0.000 105.961 0.000
201612 817.594 105.196 1,276.742
201703 0.000 105.196 0.000
201706 817.159 107.109 1,253.275
201709 0.000 109.021 0.000
201712 879.858 109.404 1,321.126
201803 0.000 109.786 0.000
201806 896.487 111.317 1,322.967
201809 0.000 115.142 0.000
201812 963.571 115.142 1,374.722
201903 0.000 118.202 0.000
201906 968.434 120.880 1,316.076
201909 0.000 123.175 0.000
201912 1,060.440 126.235 1,379.971
202003 0.000 124.705 0.000
202006 1,157.266 127.000 1,496.901
202009 0.000 130.118 0.000
202012 920.064 130.889 1,154.727
202103 0.000 131.771 0.000
202106 697.017 134.084 853.946
202109 0.000 135.847 0.000
202112 966.350 138.161 1,148.985
202203 0.000 138.822 0.000
202206 631.627 142.347 728.913
202209 0.000 144.661 0.000
202212 553.949 145.763 624.292
202303 0.000 146.865 0.000
202306 314.446 150.280 343.723
202309 0.000 151.492 0.000
202312 440.797 152.924 473.507
202403 0.000 153.035 0.000
202406 297.252 155.789 313.439
202409 0.000 157.882 0.000
202412 373.670 158.323 387.712
202503 0.000 157.552 0.000
202506 339.586 159.755 349.188
202509 0.000 162.289 0.000
202512 325.301 163.281 327.277
202603 0.000 164.272 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₹0.00 mean?
Sanofi India (BOM:500674) has a Cyclically Adjusted Book per Share of ₹0.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Sanofi India and its competitors.
Is Sanofi India's Cyclically Adjusted Book per Share too high?
Sanofi India's current Cyclically Adjusted Book per Share is ₹0.00. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Sanofi India's Cyclically Adjusted Book per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Sanofi India and its competitors. Sanofi India's current Cyclically Adjusted Book per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,404.20, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is ₹0.00. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current Cyclically Adjusted Book per Share is ₹0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,404.20. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Cyclically Adjusted Book per Share: ₹0.00
  • GF Value™: ₹4,404.20 vs. price of ₹3,369.25 (23.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score

Get the complete analysis for BOM:500674

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,369.25
Price
₹4,404.20
GF Value